Amyloid precursor protein and endosomal‐lysosomal dysfunction in Alzheimer's disease: inseparable partners in a multifactorial disease
Top Cited Papers
Open Access
- 14 June 2017
- journal article
- review article
- Published by Wiley in The FASEB Journal
- Vol. 31 (7) , 2729-2743
Abstract
Abnormalities of the endosomal–lysosomal network (ELN) are a signature feature of Alzheimer's disease (AD). These include the earliest known cytopathology that is specific to AD and that affects endosomes and induces the progressive failure of lysosomes, each of which are directly linked by distinct mechanisms to neurodegeneration. The origins of ELN dysfunction and β‐amyloidogenesis closely overlap, which reflects their common genetic basis, the established early involvement of endosomes and lysosomes in amyloid precursor protein (APP) processing and clearance, and the pathologic effect of certain APP metabolites on ELN functions. Genes that promote β‐amyloidogenesis in AD (APP, PSEN1/2, and APOE4) have primary effects on ELN function. The importance of primary ELN dysfunction to pathogenesis is underscored by the mutations in more than 35 ELN‐related genes that, thus far, are known to cause familial neurodegenerative diseases even though different pathogenic proteins may be involved. In this article, I discuss growing evidence that implicates AD gene–driven ELN disruptions as not only the antecedent pathobiology that underlies β‐amyloidogenesis but also as the essential partner with APP and its metabolites that drive the development of AD, including tauopathy, synaptic dysfunction, and neurodegeneration. The striking amelioration of diverse deficits in animal AD models by remediating ELN dysfunction further supports a need to integrate APP and ELN relationships, including the role of amyloid‐β, into a broader conceptual framework of how AD arises, progresses, and may be effectively therapeutically targeted.—Nixon, R. A. Amyloid precursor protein and endosomal–lysosomal dysfunction in Alzheimer's disease: inseparable partners in a multifactorial disease. FASEB J. 31, 2729–2743 (2017). www.fasebj.orgKeywords
Funding Information
- National Institutes of Health
- National Institute on Aging
This publication has 214 references indexed in Scilit:
- β‐ but not γ‐secretase proteolysis of APP causes synaptic and memory deficits in a mouse model of dementiaEMBO Molecular Medicine, 2012
- BACE1 Elevation is Involved in Amyloid Plaque Development in the Triple Transgenic Model of Alzheimer’s Disease: Differential Aβ Antibody Labeling of Early-Onset Axon Terminal PathologyNeurotoxicity Research, 2011
- An APPL1/Akt signaling complex regulates dendritic spine and synapse formation in hippocampal neuronsMolecular and Cellular Neuroscience, 2011
- Microarray Analysis of Hippocampal CA1 Neurons Implicates Early Endosomal Dysfunction During Alzheimer's Disease ProgressionBiological Psychiatry, 2010
- Direct binding of cholesterol to the amyloid precursor protein: An important interaction in lipid–Alzheimer's disease relationships?Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2010
- Lysosomal Proteolysis and Autophagy Require Presenilin 1 and Are Disrupted by Alzheimer-Related PS1 MutationsCell, 2010
- Endocytosis Is Required for Synaptic Activity-Dependent Release of Amyloid-β In VivoNeuron, 2008
- Alpha- and beta-secretase activity as a function of age and beta-amyloid in Down syndrome and normal brainNeurobiology of Aging, 2007
- Depletion of GGA3 Stabilizes BACE and Enhances β-Secretase ActivityNeuron, 2007
- AMPAR Removal Underlies Aβ-Induced Synaptic Depression and Dendritic Spine LossNeuron, 2006